Type 2 Diabetes

Denmark’s healthcare authority has decided to favor less expensive drugs for type 2 diabetes patients, impacting the prescription of costlier GLP-1 drugs such as Novo Nordisk’s (NYSE:NVO) Ozempic. This comes a day ahead of the company announcing its first-quarter earnings of 2024. What...

In a significant shift in strategy, Australia’s leading weight loss drug-selling start-up, Eucalyptus, has started offering Ozempic, a medication traditionally used for Type 2 diabetes treatment in the country, reports the Australian Financial Review. This comes after the company’s...

Better Therapeutics Inc (NASDAQ: BTTX) has announced primary endpoint data from its pivotal trial of BT-001 designed to use digitally delivered cognitive-behavioral therapy (nCBT) to treat type 2 diabetes. The trial enrolled 669 adults with type 2 diabetes. The primary efficacy endpoint (n=...

Institute for Clinical and Economic Review (ICER) casts doubts on Eli Lilly And Co’s (NYSE: LLY) tirzepatide, a type II diabetes candidate, about its usefulness to patients compared to the rivals. The ICER released its report, giving evidence for the drug a “B+”...

Metacrine Inc (NASDAQ: MTCR) reported topline results from its Phase 2a trial of MET409 in combination with Eli Lilly And Co's (NYSE: LLY) Jardiance (empagliflozin) in type 2 diabetes and non-alcoholic steatohepatitis (NASH).   LDL-cholesterol increases with...

Inventiva (NASDAQ: IVA) announced the design of Phase 2a combination trial of lanifibranor in patients with type 2 diabetes (T2D) and non-cirrhotic non-alcoholic steatohepatitis (NASH). The trial will assess lanifibranor combined with Eli Lilly And Co's (NYSE: LLY)...

Eli Lilly And Co (NYSE: LLY) posted data from the SURPASS-3 CGM sub-study of tirzepatide in a subpopulation of 243 participants who wore continuous glucose monitoring (CGM) for 7 to 10 days at baseline. Related Link: Eli Lilly's Tirzepatide Tops Novo's Semaglutide...

The FDA on Friday approved Bayer AG's (OTC: BAYRY) chronic kidney disease (CKD) drug Kerendia (finerenone), the first and only nonsteroidal mineralocorticoid receptor antagonist. Finerenone is indicated to reduce the risk of kidney function decline, kidney failure,...

Sanofi SA (NASDAQ: SNY) has announced new study data of Soliqua 100/33 (insulin glargine and lixisenatide injection) that met its two primary endpoints and all key secondary endpoints in a head-to-head comparison against premixed insulin in type 2 diabetes. The data were presented...

AstraZeneca Plc (NASDAQ: AZN) has reported results from the Phase 3 trial evaluating exenatide extended-release 2mg in adolescents aged 10–17 years with type 2 diabetes. This once-weekly glucagon-like peptide-1 receptor agonist significantly reduced blood sugar, as measured by...